Joakim Bo Kunkel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Joakim Bo Kunkel has a total of 112 co-authors. Here are the top co-authors by number of shared publications:
- Christian Hassager
Department of Cardiology Copenhagen University Hospital—Rigshospitalet Copenhagen Denmark
7 shared publications - Jacob Eifer Møller
Department of Cardiology, Odense Universitetshospital, Odense, Denmark
5 shared publications Lene Holmvang
5 shared publications- Lene Holmvang
Department of Cardiology, Copenhagen University Hospital—Rigshospitalet , Copenhagen
5 shared publications - Lisette Okkels Jensen
Odense University Hospital, Odense, Denmark
5 shared publications Christian Hassager
4 shared publications
Latest Publications
- Top Cited Papers
- 5 November 2026
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 395 (18) , 1818-1829
Prevalence of Silent Atherosclerosis across Adult Life
- 5 November 2026
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 395 (18) , 1818-1829
Top Cited PapersPrevalence of Silent Atherosclerosis across Adult Life
- 3 October 2026
- Published by Oxford University Press (OUP) in European Heart Journal: Acute Cardiovascular Care
Inflammation, infarct size, and 10-year mortality in STEMI patients stratified by the ORBI Risk Score: a DANAMI-3 sub-study
Aims: The ORBI Risk Score predicts in-hospital cardiogenic shock after primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI). Whether high-risk patients also have more systemic inflammation, larger infarcts, and higher long-term mortality is not known. Methods and results: In a DANAMI-3 sub-study, 1574 STEMI patients without cardiogenic shock were classified as high (ORBI ≥8, n = 273) or low risk (n = 1301). Inflammation was assessed by routine C-reactive protein (CRP), leucocyte count, and neutrophil-to-lymphocyte ratio (NLR) within 72 h of PCI, and admission mid-regional pro-adrenomedullin (MR-proADM). Infarct size was measured by cardiac magnetic resonance. Ten-year all-cause mortality was obtained from the Danish Civil Registration System. Cox models were adjusted for age, sex, comorbidity, kidney function, and randomized allocation. High-risk patients had higher peak CRP (72 vs. 11 mg/L), leucocyte count (12.8 vs. 10.4 × 109/L), NLR (6.2 vs. 3.5), and MR-proADM (0.73 vs. 0.62 nmol/L; all P < 0.001), as well as larger infarcts (final infarct size 15.7% vs. 10.1% of left ventricular mass). Ten-year mortality was 41% vs. 20% [hazard ratio (HR) 2.56, 95% CI 2.05–3.20; adjusted 1.47, 1.16–1.85]. The adjusted HR was 4.79 within 30 days and 1.27 after the first year. The score discriminated 10-year mortality less well than age alone (area under the curve 0.67 vs. 0.79). Conclusion: The ORBI Risk Score identifies STEMI patients with more inflammation, larger infarcts, and higher mortality, especially in the first year. Beyond the first year, the association was largely explained by age. Whether anti-inflammatory treatment benefits these patients is a question for randomized trials.
- 3 October 2026
- Published by Oxford University Press (OUP) in European Heart Journal: Acute Cardiovascular Care
Inflammation, infarct size, and 10-year mortality in STEMI patients stratified by the ORBI Risk Score: a DANAMI-3 sub-study
Aims: The ORBI Risk Score predicts in-hospital cardiogenic shock after primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI). Whether high-risk patients also have more systemic inflammation, larger infarcts, and higher long-term mortality is not known. Methods and results: In a DANAMI-3 sub-study, 1574 STEMI patients without cardiogenic shock were classified as high (ORBI ≥8, n = 273) or low risk (n = 1301). Inflammation was assessed by routine C-reactive protein (CRP), leucocyte count, and neutrophil-to-lymphocyte ratio (NLR) within 72 h of PCI, and admission mid-regional pro-adrenomedullin (MR-proADM). Infarct size was measured by cardiac magnetic resonance. Ten-year all-cause mortality was obtained from the Danish Civil Registration System. Cox models were adjusted for age, sex, comorbidity, kidney function, and randomized allocation. High-risk patients had higher peak CRP (72 vs. 11 mg/L), leucocyte count (12.8 vs. 10.4 × 109/L), NLR (6.2 vs. 3.5), and MR-proADM (0.73 vs. 0.62 nmol/L; all P < 0.001), as well as larger infarcts (final infarct size 15.7% vs. 10.1% of left ventricular mass). Ten-year mortality was 41% vs. 20% [hazard ratio (HR) 2.56, 95% CI 2.05–3.20; adjusted 1.47, 1.16–1.85]. The adjusted HR was 4.79 within 30 days and 1.27 after the first year. The score discriminated 10-year mortality less well than age alone (area under the curve 0.67 vs. 0.79). Conclusion: The ORBI Risk Score identifies STEMI patients with more inflammation, larger infarcts, and higher mortality, especially in the first year. Beyond the first year, the association was largely explained by age. Whether anti-inflammatory treatment benefits these patients is a question for randomized trials.
- 18 May 2026
- Published by S. Karger AG in Cardiology
- p. 1-20
A Risk Score Without a Window: The Clinical Timing Problem of ORBI (Observatoire Régional Breton sur l’Infarctus) Risk Score
Introduction Cardiogenic shock (CS) is a main cause of mortality in ST-elevation myocardial infarction (STEMI). The ORBI risk score estimates in-hospital CS risk using pre- and post-procedural angiographic variables. The study aimed to prospectively validate the ORBI risk score for predicting in-hospital CS and to assess its ability to identify post-procedural CS, when all score components are available. Methods Consecutive adult STEMI patients without CS at admission were prospectively registered at a tertiary hospital during 2022-2025. Discrimination and calibration were evaluated in all patients and among patients with post-procedural CS after leaving the catheterization laboratory. Results Among 2,713 adult patients (median age 64 years; 24% female), the median ORBI score was 4 (IQR 2-7), and 103 patients (3.8%) developed in-hospital CS. Among all patients, 80% were low-risk (ORBI ≤7) with 1.0% developing in-hospital CS; 13% were low-to-intermediate risk (ORBI 8–10) with 5.6% developing CS; 3.1% were intermediate-to-high risk (ORBI 11–12) with 23% developing CS; and 3.9% were high-risk (ORBI ≥13), of whom 40% developed in-hospital CS. The score demonstrated strong discrimination (area under the receiver operating characteristic curve (AUC) 0.89; 95%CI 0.87–0.94) for in-hospital CS and for post-procedural CS (AUC 0.87; 95%CI 0.83–0.95). In patients with in-hospital CS, 68% developed peri-procedural CS. Among patients with post-procedural CS the score substantially overestimated CS risk. Conclusions The ORBI risk score performed well at predicting in-hospital CS but markedly overestimated post-procedural CS risk. As post-procedural CS is the clinically relevant endpoint for a model incorporating post-procedural variables, the ORBI score requires recalibration before it can be used to guide post-PCI decisions.
- 18 May 2026
- Published by S. Karger AG in Cardiology
- p. 1-20
A Risk Score Without a Window: The Clinical Timing Problem of ORBI (Observatoire Régional Breton sur l’Infarctus) Risk Score
Introduction Cardiogenic shock (CS) is a main cause of mortality in ST-elevation myocardial infarction (STEMI). The ORBI risk score estimates in-hospital CS risk using pre- and post-procedural angiographic variables. The study aimed to prospectively validate the ORBI risk score for predicting in-hospital CS and to assess its ability to identify post-procedural CS, when all score components are available. Methods Consecutive adult STEMI patients without CS at admission were prospectively registered at a tertiary hospital during 2022-2025. Discrimination and calibration were evaluated in all patients and among patients with post-procedural CS after leaving the catheterization laboratory. Results Among 2,713 adult patients (median age 64 years; 24% female), the median ORBI score was 4 (IQR 2-7), and 103 patients (3.8%) developed in-hospital CS. Among all patients, 80% were low-risk (ORBI ≤7) with 1.0% developing in-hospital CS; 13% were low-to-intermediate risk (ORBI 8–10) with 5.6% developing CS; 3.1% were intermediate-to-high risk (ORBI 11–12) with 23% developing CS; and 3.9% were high-risk (ORBI ≥13), of whom 40% developed in-hospital CS. The score demonstrated strong discrimination (area under the receiver operating characteristic curve (AUC) 0.89; 95%CI 0.87–0.94) for in-hospital CS and for post-procedural CS (AUC 0.87; 95%CI 0.83–0.95). In patients with in-hospital CS, 68% developed peri-procedural CS. Among patients with post-procedural CS the score substantially overestimated CS risk. Conclusions The ORBI risk score performed well at predicting in-hospital CS but markedly overestimated post-procedural CS risk. As post-procedural CS is the clinically relevant endpoint for a model incorporating post-procedural variables, the ORBI score requires recalibration before it can be used to guide post-PCI decisions.
- Open Access
- 20 September 2025
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 135 (6) , 1618-1625
Restrictive versus liberal oxygenation in patients undergoing cardiopulmonary bypass-assisted heart surgery: a randomised controlled trial
- 20 September 2025
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 135 (6) , 1618-1625
Open AccessRestrictive versus liberal oxygenation in patients undergoing cardiopulmonary bypass-assisted heart surgery: a randomised controlled trial
- Open Access
- 17 September 2025
- Published by Elsevier in JACC: Advances
- Vol. 4 (12) , 102118
Frailty and Age as Predictors of Mortality in Acute Myocardial Infarction Complicated by Cardiogenic Shock
- 17 September 2025
- Published by Elsevier in JACC: Advances
- Vol. 4 (12) , 102118
Open AccessFrailty and Age as Predictors of Mortality in Acute Myocardial Infarction Complicated by Cardiogenic Shock
- 23 April 2025
- Published by Oxford University Press (OUP) in European Heart Journal: Acute Cardiovascular Care
- Vol. 14 (6) , 342-350
Model for end-stage liver disease incorporating albumin score is associated with short- and long-term all-cause mortality in patients with acute myocardial infarction complicated by cardiogenic shock
Aims: Liver injury is a frequent complication in patients with acute myocardial infarction complicated by cardiogenic shock (AMICS). The model for end-stage liver disease incorporating albumin (MELD-albumin) quantifies liver injury. This study assesses the association between MELD-albumin score and all-cause mortality among patients with AMICS. Methods and results: From a retrospective cohort of 1716 consecutive patients with AMICS admitted between 2010 and 2017, we included patients who survived until Day 3 and had complete laboratory data available (n = 717). The MELD-albumin was calculated using 0 to 72 h peak s-bilirubin and s-creatinine values and the lowest s-albumin value. Patients were stratified into tertiles: low, intermediate, and high MELD-albumin. The primary outcome was all-cause mortality with a follow-up of up to 14 years. Patients in the high-score group were more often female, had lower left ventricular ejection fraction, had higher lactate levels, and less suffered out-of-hospital cardiac arrest. The high-score group had a significantly higher all-cause mortality rate than the intermediate- and low-score groups at 30 days (49 vs. 35 vs. 26%, P < 0.001) and 10 years for 30-day survivors (58 vs. 46 vs. 37%, P < 0.001). Adjusted hazard ratios for mortality in the high-score group were 2.02 at 30 days [95% confidence interval (CI): 1.49–2.74, P < 0.001] and 1.86 at 10 years (95% CI: 1.18–2.92, P < 0.001). The MELD-albumin score demonstrated an area under the receiver operating curve of 0.63 (95% CI: 0.59–0.67) for predicting 30-day mortality. Conclusion: Liver injury, quantified as MELD-albumin score, was significantly associated with short- and long-term all-cause mortality among patients with AMICS.
- 23 April 2025
- Published by Oxford University Press (OUP) in European Heart Journal: Acute Cardiovascular Care
- Vol. 14 (6) , 342-350
Model for end-stage liver disease incorporating albumin score is associated with short- and long-term all-cause mortality in patients with acute myocardial infarction complicated by cardiogenic shock
Aims: Liver injury is a frequent complication in patients with acute myocardial infarction complicated by cardiogenic shock (AMICS). The model for end-stage liver disease incorporating albumin (MELD-albumin) quantifies liver injury. This study assesses the association between MELD-albumin score and all-cause mortality among patients with AMICS. Methods and results: From a retrospective cohort of 1716 consecutive patients with AMICS admitted between 2010 and 2017, we included patients who survived until Day 3 and had complete laboratory data available (n = 717). The MELD-albumin was calculated using 0 to 72 h peak s-bilirubin and s-creatinine values and the lowest s-albumin value. Patients were stratified into tertiles: low, intermediate, and high MELD-albumin. The primary outcome was all-cause mortality with a follow-up of up to 14 years. Patients in the high-score group were more often female, had lower left ventricular ejection fraction, had higher lactate levels, and less suffered out-of-hospital cardiac arrest. The high-score group had a significantly higher all-cause mortality rate than the intermediate- and low-score groups at 30 days (49 vs. 35 vs. 26%, P < 0.001) and 10 years for 30-day survivors (58 vs. 46 vs. 37%, P < 0.001). Adjusted hazard ratios for mortality in the high-score group were 2.02 at 30 days [95% confidence interval (CI): 1.49–2.74, P < 0.001] and 1.86 at 10 years (95% CI: 1.18–2.92, P < 0.001). The MELD-albumin score demonstrated an area under the receiver operating curve of 0.63 (95% CI: 0.59–0.67) for predicting 30-day mortality. Conclusion: Liver injury, quantified as MELD-albumin score, was significantly associated with short- and long-term all-cause mortality among patients with AMICS.
- 1 April 2025
- Published by Oxford University Press (OUP) in European Heart Journal: Acute Cardiovascular Care
Long-term outcomes after acute kidney injury in myocardial infarction complicated by cardiogenic shock: a retrospective, observational study
Aims: The recent DanGer shock trial found reduced mortality, but increased risk of acute kidney injury (AKI) in patients treated with a microaxial flow pump after an acute myocardial infarct with cardiogenic shock. AKI has previously been associated with increased short-term mortality, whereas data on long-term outcomes are sparse. We aimed to describe the frequency of AKI and associated risk factors as well as long-term mortality and morbidity. Methods and results: A retrospective observational study comprising patients admitted with acute myocardial infarction cardiogenic shock in Denmark between 2010 and 2017 with data on kidney function from the RETROSHOCK cohort. National health registry data enabled 10-year follow-up to assess mortality and morbidity. Kaplan-Meier estimates and competing risks regression were used to evaluate the association of AKI with the incidence of short- and long-term mortality, chronic kidney disease (CKD) and dialysis. Among 1473 patients, 44% developed AKI, 25% required renal replacement therapy (RRT). AKI development was associated with increasing age, diabetes, low ejection fraction and high lactate levels on admission (P < 0.05). Thirty-days mortality as well as mortality at 1−, 5−, and 10-years follow-up was significantly increased in patients with AKI; at 10 years follow-up mortality was increased by more than 30% (P < 0.001). The 10-year cumulative incidence of both CKD and dialysis, accounting for the competing risk of death, was significantly higher in patients treated with RRT during admission (P < 0.001). Conclusion: AKI was associated with increased short- and long-term mortality and morbidity, including CKD and dialysis, but not new cardiovascular events.
- 1 April 2025
- Published by Oxford University Press (OUP) in European Heart Journal: Acute Cardiovascular Care
Long-term outcomes after acute kidney injury in myocardial infarction complicated by cardiogenic shock: a retrospective, observational study
Aims: The recent DanGer shock trial found reduced mortality, but increased risk of acute kidney injury (AKI) in patients treated with a microaxial flow pump after an acute myocardial infarct with cardiogenic shock. AKI has previously been associated with increased short-term mortality, whereas data on long-term outcomes are sparse. We aimed to describe the frequency of AKI and associated risk factors as well as long-term mortality and morbidity. Methods and results: A retrospective observational study comprising patients admitted with acute myocardial infarction cardiogenic shock in Denmark between 2010 and 2017 with data on kidney function from the RETROSHOCK cohort. National health registry data enabled 10-year follow-up to assess mortality and morbidity. Kaplan-Meier estimates and competing risks regression were used to evaluate the association of AKI with the incidence of short- and long-term mortality, chronic kidney disease (CKD) and dialysis. Among 1473 patients, 44% developed AKI, 25% required renal replacement therapy (RRT). AKI development was associated with increasing age, diabetes, low ejection fraction and high lactate levels on admission (P < 0.05). Thirty-days mortality as well as mortality at 1−, 5−, and 10-years follow-up was significantly increased in patients with AKI; at 10 years follow-up mortality was increased by more than 30% (P < 0.001). The 10-year cumulative incidence of both CKD and dialysis, accounting for the competing risk of death, was significantly higher in patients treated with RRT during admission (P < 0.001). Conclusion: AKI was associated with increased short- and long-term mortality and morbidity, including CKD and dialysis, but not new cardiovascular events.
- 9 December 2024
- Published by Oxford University Press (OUP) in European Heart Journal: Acute Cardiovascular Care
- Vol. 14 (1) , 31-39
Neurohormonal response is associated with mortality in women with ST-elevation myocardial infarction
Aims: Women continue to have a worse prognosis following ST-elevation myocardial infarction (STEMI) compared to men, despite advancements in treatment. This study investigates whether neurohormonal biomarker differences contribute to sex-related disparities in mortality. Methods and results: A total of 1892 consecutive STEMI patients from two tertiary heart centres were included. Admission neurohormonal activation defined as pro-atrial natriuretic peptide (proANP) and mid-regional pro-adrenomedullin (MR-proADM) was measured in blood drawn prior to acute coronary angiography (CAG). The primary endpoint was 1-year mortality stratified according to sex and biomarker level. Of 1782 (94%) with biomarkers available, 476 (27%) of patients were women. They were older (68 vs. 62 years), had longer symptom-to-angiography delay (211 vs. 181 min), and displayed a higher one-year mortality rate (12% vs. 7.4%, P < 0.001) compared to men. The neurohormonal response was higher in women compared to men [median (interquartile range) proANP 1050 (671–1591) vs. 772 (492–1294) pmol/L, P < 0.001); MR-proADM 0.80 (0.63–1.03) vs. 0.70 (0.58–0.89) nmol/L, P < 0.001]. In women, a level at or above the median was independently associated with a significantly higher mortality risk when adjusting for age, left ventricular ejection fraction, diabetes, heart failure, symptom onset to CAG, left-sided culprit lesion, obesity, renal dysfunction, primary percutaneous intervention, admission systolic blood pressure, and multivessel disease (HR proANP 6.05, 95% CI 1.81–20.3, P = 0.004; HR MR-proADM 3.49, 95% CI 1.42–8.62, P = 0.007). In men, there was an independent prognostic association for proANP but not for MR-proADM (HR proANP 2.38, 95% CI 1.18–4.81, P = 0.015; HR MR-proADM 1.74, 95% CI 0.89–3.40, P = 0.11). Conclusion: Increased neurohormonal activation (MR-proADM and proANP) is associated with higher mortality in women compared to men. Neurohormonal activation may contribute to the observed sex-related differences in mortality.
- 9 December 2024
- Published by Oxford University Press (OUP) in European Heart Journal: Acute Cardiovascular Care
- Vol. 14 (1) , 31-39
Neurohormonal response is associated with mortality in women with ST-elevation myocardial infarction
Aims: Women continue to have a worse prognosis following ST-elevation myocardial infarction (STEMI) compared to men, despite advancements in treatment. This study investigates whether neurohormonal biomarker differences contribute to sex-related disparities in mortality. Methods and results: A total of 1892 consecutive STEMI patients from two tertiary heart centres were included. Admission neurohormonal activation defined as pro-atrial natriuretic peptide (proANP) and mid-regional pro-adrenomedullin (MR-proADM) was measured in blood drawn prior to acute coronary angiography (CAG). The primary endpoint was 1-year mortality stratified according to sex and biomarker level. Of 1782 (94%) with biomarkers available, 476 (27%) of patients were women. They were older (68 vs. 62 years), had longer symptom-to-angiography delay (211 vs. 181 min), and displayed a higher one-year mortality rate (12% vs. 7.4%, P < 0.001) compared to men. The neurohormonal response was higher in women compared to men [median (interquartile range) proANP 1050 (671–1591) vs. 772 (492–1294) pmol/L, P < 0.001); MR-proADM 0.80 (0.63–1.03) vs. 0.70 (0.58–0.89) nmol/L, P < 0.001]. In women, a level at or above the median was independently associated with a significantly higher mortality risk when adjusting for age, left ventricular ejection fraction, diabetes, heart failure, symptom onset to CAG, left-sided culprit lesion, obesity, renal dysfunction, primary percutaneous intervention, admission systolic blood pressure, and multivessel disease (HR proANP 6.05, 95% CI 1.81–20.3, P = 0.004; HR MR-proADM 3.49, 95% CI 1.42–8.62, P = 0.007). In men, there was an independent prognostic association for proANP but not for MR-proADM (HR proANP 2.38, 95% CI 1.18–4.81, P = 0.015; HR MR-proADM 1.74, 95% CI 0.89–3.40, P = 0.11). Conclusion: Increased neurohormonal activation (MR-proADM and proANP) is associated with higher mortality in women compared to men. Neurohormonal activation may contribute to the observed sex-related differences in mortality.